Rheumatoid Arthritis

MD IQ

News

Novel CCR-1 Antagonist Shows Promise in RA

Major Finding: ACR20 response rates among day 1 eligible subjects in an intention-to-treat analysis were 56%, 44%, and 30%, in the 200-mg, 100-mg...

Pages